Europe Startup Funding Rounds
Startups raising capital across Europe. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 1,357 Jan 1 – Oct 11, 2026
- Disclosed funding
- $60.9B 1151 disclosed amounts
- Median round
- $6.8M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| M MycoverseCompany profile Developing fungal-based biological crop protection solutions using AI-driven discovery platform Developing fungal-based biological crop protection solutions using AI-driven discovery platform | €2.4M | Pre-SeedPre-seed | Agritech | Denmark | Investors | |
| F FlinkCompany profile Operates a network of local fulfilment hubs for rapid delivery of everyday groceries and household items Operates a network of local fulfilment hubs for rapid delivery of everyday groceries and household items | $100M | Growth | Ecommerce | Germany | Investors | |
| A ALORACompany profile Agricultural biotechnology company developing gene-edited crop traits to improve yield under heat and salinity stress. Agricultural biotechnology company developing gene-edited crop traits to improve yield under heat and salinity stress. | Undisclosed | Undisclosed | Agritech | United Kingdom | Investors | |
| b Develops an AI-powered bioproduction platform for industrial ingredients | €7M | Seed | Biotech | France | Investors | |
| G GroundhawkCompany profile Provides real-time AI-powered 3D capture for underground infrastructure mapping and documentation Provides real-time AI-powered 3D capture for underground infrastructure mapping and documentation | €2M | Seed | Proptech | Finland | Investors | |
| PM Polares MedicalCompany profile Develops the MRace Posterior Leaflet Replacement system, a transcatheter therapy for mitral regurgitation Develops the MRace Posterior Leaflet Replacement system, a transcatheter therapy for mitral regurgitation | $50M | Series CSeries C+ | Healthtech | Switzerland | Investors | |
| A AntiverseCompany profile Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. | $9.3M | Series A | Healthtech | United Kingdom | Investors | |
| B Develops AI platform for targeted crop protection solutions | $3.8M | Seed | Agritech | United Kingdom | Investors | |
| GE Multinational producer and distributor of table eggs | $1B | StrategicUndisclosed | Agritech | Luxembourg | Investors | |
| OB Develops AI-driven models to decode human microbiology | $3.5M | Pre-SeedPre-seed | Biotech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1High-Tech Gründerfonds
TODAY, Finches, Kontext
38rounds4led - 2Antler
Boxd, Creem, Souk
23rounds0led - 3Y Combinator (YC)
Sensible Biotechnologies, Revnu, Spott
21rounds1led - 4General Catalyst
Complir, Integral, Intropy
20rounds1led - 5Index Ventures
Spiko, Nomos, Wonderful
19rounds2led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.